Following DSMB recommendation, the Company has voluntarily paused enrollment and dosing in the BEACON-IPF Phase 2b trial and ...

Pliant Therapeutics (PLRX) announced that following a prespecified data review and recommendations by the trial’s independent Data Safety ...

The FDA accepts and grants priority review to INSM's NDA for brensocatib to treat patients with non-cystic fibrosis bronchiectasis. A decision is due on Aug. 12, 2025.

Insmed's promising drug pipeline includes Brensocatib and Arikayce. See why INSM stock is a strong pick with multi-billion ...

Low total cholesterol levels were tied to an increased risk of death for pulmonary fibrosis patients with disease of unknown cause in a study.

Chair and CEO of Insmed Inc. (NASDAQ:INSM), recently executed a significant stock transaction amid the company's impressive 178% stock surge over the past year. According to a recent SEC filing, Lewis ...

Michael Alexander Smith, the Chief Legal Officer of Insmed Inc. (NASDAQ:INSM), has recently sold a significant portion of his holdings in the company. According to a recent SEC filing, Smith sold ...

Bristol-Myers Squibb beat Q4 earnings expectations, but the stock fell due to lowered 2025 revenue guidance and patent ...

Ohtuvayre™is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients ...

The first recipient of a gene-edited pig kidney died from cardiac causes 52 days after xenotransplantation. The world's first ...

Drying wet clothing on racks in poorly ventilated spaces could increase mould growth in a home, which is associated with poor health.

Despite new medication, cystic fibrosis often leads to permanent lung damage. Working with an international team, researchers from the Technical University of Munich (TUM) have discovered that the ...